Many transplantable T-cell lymphomas contain amplified copies of endogenous mouse mammary tumor virus (MMTV) DNA. We suspect that this is a novel process unlike normal retrovirus infection because of the following. (i) There is size conservation of novel virus-cell junction fragments in these tumors, indicating site specificity of the amplified proviruses. (ii) Abelson-transformed clones can acquire amplified MMTV proviruses within a few in vivo passages. This pattern of acquired proviruses is then stable for long periods. (iii) No mature MMTV proteins, or viral particles, are detectable in C57BL (B6) lymphomas, suggesting that particle infection is not required for amplification. (iv) Rearrangements of endogenous proviruses are detected in the gag-pol region. Such rearrangements have not been detected in MMTV-infected mammary tumors. The mechanism suggested for the amplification process are gene amplification (generation of tandem head-to-tail repeats), reintegration through RNA intermediates, reintegration through DNA intermediates (transposition), and gene conversion. I propose to distinguish between these models by a series of experiments which include restriction mapping and subcloning of MMTV proviruses and their flanking sequences from a cloned library of B6 DNA. An in vitro system for studying MMTV amplification also will be developed. A secondary objective of this proposal is to study the function of amplified MMTV in lymphomas. This will be accomplished by mapping MMTV proviral sites by somatic cell hybridization. In addition transcription of MMTV proviruses and their flanking sequences will be monitored. Study of the amplification of endogenous MMTV DNA is important for achieving the long-term objective of understanding the transmission and regulation of endogenous viruses.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA034780-03
Application #
3172588
Study Section
Virology Study Section (VR)
Project Start
1984-07-01
Project End
1988-03-31
Budget Start
1986-07-01
Budget End
1988-03-31
Support Year
3
Fiscal Year
1986
Total Cost
Indirect Cost
Name
University of Texas Austin
Department
Type
Schools of Arts and Sciences
DUNS #
City
Austin
State
TX
Country
United States
Zip Code
78713
Maitra, Urmila; Seo, Jin; Lozano, Mary M et al. (2006) Differentiation-induced cleavage of Cutl1/CDP generates a novel dominant-negative isoform that regulates mammary gene expression. Mol Cell Biol 26:7466-78
Seo, Jin; Lozano, Mary M; Dudley, Jaquelin P (2005) Nuclear matrix binding regulates SATB1-mediated transcriptional repression. J Biol Chem 280:24600-9
Bhadra, Sanchita; Lozano, Mary M; Dudley, Jaquelin P (2005) Conversion of mouse mammary tumor virus to a lymphomagenic virus. J Virol 79:12592-6
Zhu, Quan; Maitra, Urmila; Johnston, Dennis et al. (2004) The homeodomain protein CDP regulates mammary-specific gene transcription and tumorigenesis. Mol Cell Biol 24:4810-23
Erturk, Ece; Ostapchuk, Philomena; Wells, Susanne I et al. (2003) Binding of CCAAT displacement protein CDP to adenovirus packaging sequences. J Virol 77:6255-64
Mustafa, Farah; Bhadra, Sanchita; Johnston, Dennis et al. (2003) The type B leukemogenic virus truncated superantigen is dispensable for T-cell lymphomagenesis. J Virol 77:3866-70
Broussard, Dana R; Mertz, Jennifer A; Lozano, M et al. (2002) Selection for c-myc integration sites in polyclonal T-cell lymphomas. J Virol 76:2087-99
Zhu, Quan; Dudley, Jaquelin P (2002) CDP binding to multiple sites in the mouse mammary tumor virus long terminal repeat suppresses basal and glucocorticoid-induced transcription. J Virol 76:2168-79
Dudley, J P; Mertz, J A; Rajan, L et al. (2002) What retroviruses teach us about the involvement of c-Myc in leukemias and lymphomas. Leukemia 16:1086-98
Mertz, J A; Mustafa, F; Meyers, S et al. (2001) Type B leukemogenic virus has a T-cell-specific enhancer that binds AML-1. J Virol 75:2174-84

Showing the most recent 10 out of 34 publications